Clinical Trial Update: Effect of Lamotrigine on Cognition in NF1 [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating lamotrigine for cognitive enhancement in Neurofibromatosis Type 1 was terminated after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Lamotrigine (lamotrigine)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Neurofibromatosis Type 1 | Phase 2, Phase 3 | Status: TERMINATED